Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart Tags
Bone & JointCardiovascularCase Study & ProceedingCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
Smart Search
Effects of PCSO-524® on Treatment of Cranial Cruciate Ligament Rupture in Dogs after Tibial Plateau Leveling Osteotomy (TPLO) and Physical Rehabilitation
Authors:
Male Labrador Retriever dog aged 3 years was suffering from left hind limb pain.
Hematological parameters were normal. Radiographic image showed swollen left stifle joint and mild osteoarthritis. Cranial cruciate ligament rupture was diagnosed.
Firocoxib 5 mg/kg sid for 2 weeks and 2 capsules of ANTINOL ® bid for 1 month were prescribed.
Tibial Plateau Leveling Osteotomy (TPLO) was operated on the dog. Post operation care included Firocoxib 5 mg/kg sid for 2 weeks and 2 capsules of ANTINOL ® bid in combination with physical rehabilitation using laser stimulation and later exercise therapy was added. Clinical signs were improved as indicated by lameness score, muscle mass and range of motion.
Five months after the operation, the dog expressed signs of right hind limb pain and radiographic image showed swollen right stifle joint and mild osteoarthritis of left stifle joint. Partial tear of cranial cruciate ligament was diagnosed. The dog was treated for thrombocytopenia until recovered before Tibial Plateau Leveling Osteotomy (TPLO) was operated on the right knee 3 months later. Radiographic examination post operation showed increased inflammation of both stifle joints.
Surgical treatment was used in combination with medication which included NSAIDs during the first 2 weeks post operation, ANTINOL®, and physical rehabilitation in order to reduce pain and inflammation. The treatment gave satisfactory results. The dog was able to use its legs without lameness, muscle was stronger, stifle angle was better and general health was improved.
Use of PCSO-524® in Combination with Prednisolone for Treatment of Spinal Cord Injury from Disc Protrusion in Dogs
Male Shih tzu dog aged 9 years and 1 month was diagnosed with limb paralysis after jumping 4 days prior to the hospital visit.
The dog showed weak response of forelimb reflex and severe neck pain. X-ray examination showed block vertebrae at C3 and C4.
Magnetic resonance imaging (MRI) examination found mild disc protrusion, compression on spinal cord and myelopathy at C4 and C5 with compression on the right dorsal lamina.
Prednisolone and gabapentin were prescribed to reduce inflammation and pain, respectively.
Follow-up after reduction of prednisolone showed that the dog fell more often while walking and slight neck pain was present. Prednisolone dosage was then increased and PCSO-524® was prescribed to reduce inflammation of the spinal cord. Later examination found that the dog could walk without falling, both forelimbs showed normal reflex, and signs of neck pain disappeared. Termination of prednisolone was then started without any recurrent clinical signs.
After continuous treatment with PCSO-524® for 6 weeks, the dog could walk normally, both forelimbs showed normal reflex, and the ALK level was nearly back to the level prior to the treatment.
Effects of PCSO-524® on Inflammation Control in Cats with Chronic Renal Disease after Keratectomy and Conjunctival Pedicle Graft for Treatment of Corneal Sequestrum from Indolent Ulcer
Authors:
A female spayed cat aged 13 years with chronic renal disease later affected with indolent ulcer, and consequently followed by corneal sequestrum.
After azotemia was controlled, the cat was surgically treated with keratectomy that used conjunctival pedicle graft for suture closure.
The cat received 4mg/kg Tolfenamic acid (Tolfedine®, Vetoquinol, Best Agro; Thailand) for 3 days, 2.5 mg/kg Doxycycline monohydrate (Vibravet®, Zoetis, Thailand) for 2 weeks and 1 tablet per day of New Zealand Green-lipped mussel extract, PCSO-524® (Vetz Petz Antinol®, DKSH, Thailand) for long-term control of inflammation.
The latter was used as an antioxidant and alternative to Non-steroid, which is a contradiction for chronic renal failure.
The cat showed decreased severity of inflammation, normal clinical symptoms, and fine control of azotemia.
It is concluded that PCSO-524® (Vetz Petz Antinol®) can be used to support long-term anti-inflammation treatment and reduce the damage in cats with medical contraindication due to chronic renal disease
Effectiveness of Disease Modifying Osteoarthritis Agents and Carprofen for Treatment of Canine Osteoarthritis
A prospective, randomized, single-blinded study was conducted to evaluate and compare the effectiveness of disease modifying osteoarthritis agents (DMOAAs) and carprofen by using force plate gait analysis and orthopaedic assessment score (OAS) in osteoarthritic dogs.
Forty dogs with hip and/or stifle osteoarthritis (OA) were assigned randomly into four treatment groups:
PCSO-524, treated with a marine-based fatty-acid compound; GC-ASU, treated with a combination of glucosamine-chondroitin sulphate and avocado/soybean unsaponifiables; CPF, treated with carprofen; and CPF-PCSO, treated with a combination of carprofen and PCSO-524. Each group received the therapeutic agent orally for four weeks.
Peak vertical force (PVF), OAS, haematology and blood chemistry values were evaluated before treatment, and on the second and fourth weeks post-treatment.
No significant effect was found in the PVF, OAS and blood values among the four treatment groups.
Effect of PCSO-524 on OA Biomarkers and Weight Bearing Properties in Canine Shoulder and Coxofemeral Osteoarthritis
This trial included 66 mixed breed dogs with x-ray confirmed OA split into two treatment groups for 24 weeks. These were 1) PCSO-524 (5 mg/kg) and 2) fish oil (2,000 mg/d). The dogs were all placed on a standardised diet to minimise variability.
The results suggest that PCSO-524 is protective against cartilage breakdown in dogs with osteoarthritis.
The Effectiveness of Marine Based Fatty Acid Compound and NSAIDs for the Treatment of Canine Osteoarthritis: a preliminary study
The Objectives of this study were to investigate the effectiveness of PCSO-524, NSAIDs and combination of NSAIDs and PCSO-524 in the treatment of canine osteoarthritis through the use of force plate gait analysis.
Study Design: A prospective block-randomized single-blinded study.
Animals: Thirty client-owned dogs that had clinical and radiographic evidences of hip or stifle osteoarthritis.
Effects of Dietary Polyunsaturated Fatty Acid Supplement on Healthy Beagle Dogs
Authors:
A randomized complete blocked design was assigned to 40 healthy Beagle dogs aged between 1 to 3 years old. All dogs were separated into 4 groups, each of which had 5 males and 5 females.
Adaptation and test periods were of 2 and 8 weeks duration, respectively.
Four dietary treatments were composed of basal diet plus 20 empty capsules as placebo (negative control), basal diet plus 2 (the recommended dose), 6 (3 times the recommended dose) and 20 capsules (10 times the recommended dose) of n-3 PUFAs (PCSO-524®: Antinol®).
Application of the Polyunsaturated fatty acid compound PCSO-524 in the post operative recovery of dogs that have had stifle surgery
World Small Animal Veterinary Assoc.
38th Annual Congress 6-9 March 2013, Auckland, New Zealand
The clinical outcomes of the use of PCSO-524 in 28 dogs that had undergone surgery on the stifle (which included correction of the patellar luxation and correction of cranial cruciate ligament rupture) were studied at the Small Animal Teaching Hospital, at Chulalongkorn University, Bangkok, Thailand.
Twenty-eight dogs that undergone both stifle surgery were included in our study. All test subjects had been given pre-emptive analgesia (morphine sulfate). NSAIDs and glucosamine had been administered before the surgery.
Two postoperative treatments were:
- NSAIDs treatment for one week in combination with glucosamine sulfate;
- only PCSO-524 treatments.
The Effects of PCSO-524 Extract on Vital Signs, Complete Blood Count, and Blood Chemistry in Clinically-Healthy Normal Cats
Authors:
Chronic pain is commonly caused by degenerative disease, which is under diagnosed in cats.
PCSO-524 is an extract of Perna canaliculus, a known source of Omega-3 polyunsaturated fatty acids (PUFAs) with anti-inflammatory properties. Lipids extracted from the New Zealand green-lipped mussel (NZGLM) contain a complex mixture of mainly phospholipids (PL, 57-79%), triglycerides (TG, 10-25%), free fatty acids (FFA, 7-12%) and sterols (ST, 12-18%)
PCSO-524 is a source of omega-3 polyunsaturated fatty acids with anti-inflammatory properties commonly used to treat osteoarthritis in human beings and dogs.
The purpose of this study was to study the effects of PCSO-524 extract on vital signs, completed blood count, and blood chemistry in clinically-healthy normal cats.
The Preliminary study of the Clinical outcome of using the PCSO-524 polyunsaturated fatty acid compound (Antinol) in the treatment of Canine Osteoarthritis and degenerative spinal diseases
Authors:
The clinical outcome of PCSO-524 application in the treatment of canine osteoarthritis and spinal disorder was studied at the Small Animal Teaching Hospital, Chulalongkorn University.
Eighty-four dogs were included in our study. Thirty-one dogs showed signs of osteoarthritis (OA) in both hip joints and shoulder joints; 33 dogs had OA in stifle joints from cranial cruciate ligament rupture; and 20 dogs had neurological signs of the cauda equina syndrome.
All affected dogs were treated by 50 mg/ 10 kg of PCSO-524, PO for twelve weeks.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted
